Audio

Community Oncology Podcast - Vandetanib in advanced hereditary medullary thyroid cancer


 

The roles of the estrogen receptor signaling pathway in endocrine agents for breast cancer in postmenopausal women and of vandetanib in treating patients with advanced hereditary medullary thyroid cancer are among the topics from the August issue of Community Oncology that are discussed by Dr. David H. Henry.

Recommended Reading

Two Factors Predict Postradiotherapy Swallowing Difficulties
MDedge Hematology and Oncology
Low EGFR Expression Predicts ARCON Benefit in Laryngeal Cancer
MDedge Hematology and Oncology
Larynx Preservation Studies Should Consider Treatment Impact
MDedge Hematology and Oncology
HPV-Related Oral Cancer Incidence Spikes Sharply
MDedge Hematology and Oncology
HPV-Related Oral Cancer Incidence Spikes Sharply
MDedge Hematology and Oncology
Palliative Care in the Comfort of Home
MDedge Hematology and Oncology
Cancer Stage Not a Significant Factor in Radioiodine Use
MDedge Hematology and Oncology
COMMUNITY TRANSLATIONS Vandetanib in advanced hereditary medullary thyroid cancer
MDedge Hematology and Oncology
First-bite syndrome: a novel complication of carotid body paraganglioma resection
MDedge Hematology and Oncology
Community Translations Commentary Promising data, but challenges remain in selecting appropriate TKIs
MDedge Hematology and Oncology